文献速递神经核医学放射性药物与辐射防护

英国痴呆平台PET/MR harmonisation与重测研究:全国网络内PET可重复性与再现性评估

The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-04-29

74次扫描的CL值显示极佳的重测一致性(ICC=0.968),排除一个衰减校正相关离群值后ICC升至0.987,平均重测变异性为2.58%。研究表明harmonised PET/MR可实现与PET/CT相当的高可靠性,支持其用于研究和治疗试验中的定量淀粉样蛋白成像。

要点

  • harmonised PET/MR在8台扫描仪网络内淀粉样蛋白定量重测ICC达0.968,排除1个衰减校正离群值后为0.987。
  • 平均重测变异性为2.58%,重复性与再现性条件、扫描仪类型及示踪剂间无统计学显著差异。
  • CL测量与三次独立盲法视觉判读高度一致,支持PET/MR用于研究和治疗试验中的定量淀粉样蛋白成像。

核心结论

  • harmonised PET/MR可实现与PET/CT相当的高可靠性,支持其用于研究和治疗试验中的定量淀粉样蛋白成像。
  • 尽管衰减图的准确性需要检查,本研究提供了开放的图像和原始PET/MR数据资源供方法学进一步发展。

研究设计与样本

  • 在英国8台PET/MR扫描仪网络内开展多中心harmonisation与严格重测研究。
  • 重测扫描在same-site repeatability或multi-site reproducibility条件下进行,应用harmonised采集与重建协议,以Centiloid(CL)量表定量淀粉样蛋白负荷。

主要发现

  • 74次扫描的CL值显示极佳的重测一致性(ICC=0.968),排除一个衰减校正相关离群值后ICC为0.987。
  • 平均重测变异性为2.58%。
  • 重复性与再现性条件、扫描仪类型或示踪剂之间未观察到统计学显著差异。
  • CL测量与三次独立盲法视觉判读高度一致。

临床怎么用

  • harmonised PET/MR可用于研究和治疗试验中的定量淀粉样蛋白成像。
  • 应用时需检查衰减图的准确性。

局限性

  • 衰减图的准确性仍需检查,且分析中排除了一例衰减校正相关离群值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Positron emission tomography combined with magnetic resonance imaging (PET/MR) has not yet achieved the level of adoption of PET/CT. This study aimed to harmonise PET imaging protocols across a national PET/MR network and to quantitatively assess whether PET/MR can achieve reliability comparable to PET/CT. While previous PET test-retest studies have demonstrated good repeatability, they have typically been limited to small cohorts or restricted site configurations. METHODS: We conducted a multi-site harmonisation and rigorous test-retest study across the network of eight PET/MR scanners. Thirty-seven healthy older participants (65-90 years) underwent harmonised one-hour amyloid PET/MR scans using either [[Formula: see text]F]flutemetamol or [[Formula: see text]F]florbetaben on two occasions. Retest scans were performed under conditions of same-site repeatability or multi-site reproducibility. Harmonised acquisition and reconstruction protocols were applied, and amyloid burden was quantified on the Centiloid (CL) scale. RESULTS: CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier. Mean test-retest variability was 2.58%. No statistically significant differences were observed across repeatability versus reproducibility conditions, scanner types, or tracers. CL measurements were highly consistent with three independent blinded visual reads. CONCLUSION: This study demonstrates that harmonised PET/MR achieves high reliability comparable to PET/CT. Although the accuracy of attenuation maps requires checks, this study supports the use of PET/MR for quantitative amyloid imaging in research and therapeutic trials, and provides a valuable open resource of image and raw PET/MR data for further methodological development.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Markiewicz PJ, Thompson G, Wardlaw JM, et al. The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network. Eur J Nucl Med Mol Imaging. 2026. PMID: 42050257. doi:10.1007/s00259-026-07885-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。